Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Versa Vascular named ex-Medtronic CEO Bill Shields and lifted its AdapTR tricuspid repair Series C to $42 million, funding a U.S. Early Feasibility Study.
Aura Life Science wants bugs that eat light instead of sugar. We debate whether photosynthetic biomanufacturing can actually beat precision fermentation for biologics.
One hundred million dollars for a company that has yet to disclose a single clinical program. Aureka's bet is that owning the experiment loop beats owning the best algorithm.
KaloCyte's ErythroMer is a freeze-dried artificial red blood cell that needs no refrigeration and works for any blood type. DARPA has put $46 million behind it and targets FDA authorization by 2029. The engineering, the $7 billion market, and what killed every substitute before it.
InduPro raised $77M led by The Column Group — with Merck, Sanofi, Lilly, Vida Ventures, Emerson Collective, Euclidean Capital and Solasta Ventures — the same day its proximity-guided bispecific ADC IDP-001 (EGFR×TAPA-E1) dosed its first patient. Why spatial targeting matters now.
Microbes on a cathode can turn surplus wind power and CO2 into acetate, bioplastics and single-cell protein — if the electrons arrive on a schedule. A Stanford run held 2 mM/h under intermittency; a 2026 review says the ceiling has moved from biology to reactor and grid design.
A 13-person startup raised $152 million to run a global Phase 3 in HHT, a rare vascular disorder with no approved therapy. The data that could make engasertib the first approved treatment, and the risks that remain.
The US federal government has obligated $41.3M to Verily for wastewater testing as the National Wastewater Surveillance System turns from pandemic scramble into permanent infrastructure. Biobot, which built the network, lost the federal contract and then Massachusetts.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
